cancer immunotherapy

cancer immunotherapy is a form of biological therapy that harnesses the power of the body's own immune system to fight cancer. It represents a paradigm shift in oncology, moving beyond traditional treatments like chemotherapy and radiation therapy. This approach includes strategies to stimulate immune responses or provide immune system components, such as engineered immune cells or antibodies.

Overview

The conceptual foundation for leveraging the immune system against tumors dates back to observations by William Coley in the late 19th century, who noted regressions after bacterial infections. The modern field was propelled by foundational work in immunology by scientists like James P. Allison and Tasuku Honjo, who elucidated immune checkpoint pathways. Their discoveries, recognized with the Nobel Prize in Physiology or Medicine, led to the development of revolutionary drugs. Major research and clinical advances are often presented at conferences like the annual meeting of the American Society of Clinical Oncology.

Types of immunotherapy

A primary category is immune checkpoint inhibitors, which block proteins like PD-1 or CTLA-4 used by cancer cells to evade detection; drugs such as pembrolizumab and ipilimumab are prominent examples. Adoptive cell transfer, particularly CAR T-cell therapy, involves engineering a patient's own T cells to target specific tumor antigens, with approved therapies like tisagenlecleucel for certain leukemias. Cancer vaccines, such as sipuleucel-T for prostate cancer, aim to prime the immune system against tumor-associated antigens. Other approaches include cytokine therapy using agents like interleukin-2 and monoclonal antibody treatments like rituximab and trastuzumab.

Mechanisms of action

These therapies work by overcoming the immunosuppressive tactics of the tumor microenvironment. Checkpoint inhibitors essentially release the "brakes" on T cells, allowing them to recognize and attack malignant cells. CAR T-cell therapy involves genetically modifying T lymphocytes to express chimeric antigen receptors that directly bind to surface proteins on B-cell lymphoma or acute lymphoblastic leukemia cells. Cytokine therapies boost the proliferation and activity of immune cells systemically. Monoclonal antibodies can directly target cancer cells for destruction by the immune system or block growth-signaling pathways.

Clinical applications

Immunotherapy has become a standard of care for numerous malignancies. It is widely used in advanced melanoma, non-small cell lung cancer, and renal cell carcinoma, often following studies led by institutions like the National Cancer Institute. CAR T-cell therapy is approved for specific B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Agents like pembrolizumab are used for Merkel cell carcinoma and microsatellite instability-high tumors across various cancer types. Combination approaches with chemotherapy or radiation therapy are actively explored in clinical trials at centers like the MD Anderson Cancer Center.

Challenges and side effects

A significant limitation is that not all patients respond, partly due to tumor factors like low mutational burden or a lack of infiltrating T cells. Treatments can also induce unique and potentially severe immune-related adverse events, such as colitis, pneumonitis, or endocrine dysfunction, requiring careful management. The high cost of these therapies, exemplified by drugs from companies like Bristol Myers Squibb and Merck & Co., presents substantial access and economic challenges for healthcare systems worldwide.

Research and future directions

Current investigations focus on identifying predictive biomarkers, such as PD-L1 expression, to better select patients. Strategies to overcome resistance include combining different immunotherapies or targeting other immune cells like macrophages and natural killer cells. Research into neoantigen-based personalized vaccines, as pursued by initiatives like the Cancer Moonshot, is a promising frontier. Efforts are also underway to expand efficacy to "cold" tumors and to manage toxicity more effectively through studies supported by organizations like the American Association for Cancer Research.